belantamab subcutaneous / GSK - LARVOL DELTA

Belantamab Mafodotin Triplets Versus Active-Control Triplets in Relapsed or Refractory Multiple Myeloma (SOHO 2026) - "Other belantamab studies were excluded because they evaluated monotherapy, earlier-phase combinations, or regional expansion cohorts or were duplicate updated analyses, rather than independent phase 3 randomized triplet comparisons. Interventions: DREAMM-7 compared belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone. DREAMM-8 compared belantamab mafodotin, pomalidomide, and dexamethasone versus pomalidomide, bortezomib, and dexamethasone... Belantamab mafodotin-containing triplets significantly improve PFS in patients with RRMM, compared with active-control triplets, with consistent benefit observed across two pivotal phase 3 studies. These findings support belantamab-based triplets as clinically important off-the-shelf BCMA-directed options in RRMM, while emphasizing the importance of careful ocular toxicity monitoring and mitigation strategies. BCMA: B-cell maturation antigen, CI: confidence interval, MRD: measurable..."

Hematological Malignancies • Multiple Myeloma • Oncology

DynaMMic-2: A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care (clinicaltrials.gov) - P1 | N=22 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology